GMT

Rockwell Automation to Present at BofA Global Industrials Conference

Retrieved on: 
Wednesday, March 6, 2024

Rockwell Automation, Inc. (NYSE: ROK) Senior Vice President, Intelligent Devices, Tessa Myers, will present at BofA Global Industrials Conference on Wednesday, March 20, 2024, in London.

Key Points: 
  • Rockwell Automation, Inc. (NYSE: ROK) Senior Vice President, Intelligent Devices, Tessa Myers, will present at BofA Global Industrials Conference on Wednesday, March 20, 2024, in London.
  • The fireside chat will be webcast beginning at approximately 2:50 p.m. GMT and will be available on the Rockwell Automation Investor Relations website at www.rockwellautomation.com/en-us/investors.html .

CCC to Host Publisher Panel on Copyright and AI at 2024 London Book Fair

Retrieved on: 
Tuesday, March 5, 2024

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host, “ Publishers, Copyright & AI: Taking Action ” at the 2024 London Book Fair on Tuesday, 12 March, 10:30 – 11:00am GMT in the Tech Theatre.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host, “ Publishers, Copyright & AI: Taking Action ” at the 2024 London Book Fair on Tuesday, 12 March, 10:30 – 11:00am GMT in the Tech Theatre.
  • “This panel will continue the important discussion of how publishers are addressing the balance of respect for copyright and responsible AI development.”
    The London Book Fair panel follows a series of Town Hall events on the topic of AI:
    “ The Heart of the Matter: Copyright, AI Training and LLMs ,” where experts discussed technical and legal aspects of the use of copyrighted content in AI systems.
  • “ ChatGPT & Information Integrity ” explored the evolving nature of originality and authenticity in a world of AI and discussed the rapid growth of generative AI tools.
  • CCC’s dedicated resource page, Intersection of AI & Copyright , features informational resources for creators, publishers, rightsholders, technologists, media representatives, policy makers, intellectual property attorneys, and others.

Saviynt to Demonstrate Cutting-Edge Solutions at the 2024 Gartner® Identity & Access Management Summit in London

Retrieved on: 
Thursday, February 29, 2024

Gartner Identity & Access Management Summit 2024 -- Saviynt , a leading provider of cloud-native identity and governance platform solutions, today announced it will demonstrate its leading Enterprise Identity Cloud (EIC) platform at the 2024 Gartner Identity & Access Management Summit taking place 4 - 5 March in London.

Key Points: 
  • Gartner Identity & Access Management Summit 2024 -- Saviynt , a leading provider of cloud-native identity and governance platform solutions, today announced it will demonstrate its leading Enterprise Identity Cloud (EIC) platform at the 2024 Gartner Identity & Access Management Summit taking place 4 - 5 March in London.
  • “This year the team is excited to showcase the only converged cloud identity platform that provides intelligent access and governance for any app, any identity and any cloud.
  • The discussion will dive into the transformative impact of converged identity on identity security projects.
  • Moller-Maersk
    Meet with Saviynt at Gartner IAM London:
    Saviynt Onsite: During expo hours attendees can stop by Booth #300 or reserve a demo of Saviynt’s EIC platform.

Hunting PLC (“Hunting” or “the Company” or “the Group”) Results for the year ended 31 December 2023

Retrieved on: 
Thursday, February 29, 2024

The global outlook for energy in the year ahead will be driven by similar themes to those reported in 2023.

Key Points: 
  • The global outlook for energy in the year ahead will be driven by similar themes to those reported in 2023.
  • The Middle East will also likely show a continuation of the activity levels reported in 2023.
  • The Enpro business should also support this growth profile given the orders secured in the second half of 2023.
  • For access to the Financial Statements and Notes to the Accounts for the year ended 31 December 2023 please click on the following link.

Watts Water Technologies to Participate in the Northcoast Research Water & Environmental 1x1 Summit in London

Retrieved on: 
Monday, February 26, 2024

Watts Water Technologies, Inc. (NYSE: WTS) today announced that Shashank Patel, Chief Financial Officer; Andre Dhawan, Chief Operating Officer; and Diane McClintock, Senior Vice President FP&A and Investor Relations will participate in the Northcoast Research Water & Environmental 1x1 Summit on Thursday, March 7, 2024 at 8:00 a.m. (GMT) at The Tower Hotel, St Katharine's Way, London E1W 1LD, United Kingdom.

Key Points: 
  • Watts Water Technologies, Inc. (NYSE: WTS) today announced that Shashank Patel, Chief Financial Officer; Andre Dhawan, Chief Operating Officer; and Diane McClintock, Senior Vice President FP&A and Investor Relations will participate in the Northcoast Research Water & Environmental 1x1 Summit on Thursday, March 7, 2024 at 8:00 a.m. (GMT) at The Tower Hotel, St Katharine's Way, London E1W 1LD, United Kingdom.
  • Watts Water Technologies, Inc., through its family of companies, is a global manufacturer headquartered in the USA that provides one of the broadest plumbing, heating, and water quality product lines in the world.
  • Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions to control the efficiency, safety, and quality of water within commercial, residential, and industrial applications.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240226140633/en/

CCC to Host Town Hall on Copyright, Artificial Intelligence, and the Training of Large Language Models

Retrieved on: 
Thursday, February 22, 2024

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host the Town Hall event “The Heart of the Matter: Copyright, AI Training and LLMs” via LinkedIn Live on Thursday, 29 February, 11:00 EST/16:00 GMT.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host the Town Hall event “The Heart of the Matter: Copyright, AI Training and LLMs” via LinkedIn Live on Thursday, 29 February, 11:00 EST/16:00 GMT.
  • “There is growing focus on the use of copyrighted materials in training as well as how materials are being retained and reused in LLMs within AI systems,” said Tracey Armstrong, President and CEO, CCC.
  • In October, CCC hosted a Town Hall on “ AI, Licensing and the Path Forward ,” which focused on how voluntary collective licensing is a proven way to use large collections of copyrighted materials with permission and why AI technologies must address important concerns over equity, transparency, and authenticity.
  • Another previous CCC Town Hall event, “ ChatGPT & Information Integrity ,” explored the evolving nature of originality and authenticity in a world of AI and discussed the rapid growth of generative AI tools.

Axway Announces Entering Into Exclusive Discussions to Acquire Most of Sopra Banking Software Activities

Retrieved on: 
Wednesday, February 21, 2024

Axway (Paris:AXW) today announces entering into exclusive discussions regarding the potential acquisition of most of Sopra Banking Software (“SBS”) activities, which are currently part of Sopra Steria Group.

Key Points: 
  • Axway (Paris:AXW) today announces entering into exclusive discussions regarding the potential acquisition of most of Sopra Banking Software (“SBS”) activities, which are currently part of Sopra Steria Group.
  • Axway would acquire the SBS activities concerned by the operation for an enterprise value of €330m.
  • Sopra Steria granted exclusive rights to Axway and Sopra GMT to negotiate the envisaged transactions.
  • Pierre Pasquier, Chairman of Axway, Sopra Steria and Sopra GMT, declared:
    "Axway's proposed acquisition of most of SBS's activities represents an undeniable strategic opportunity for both companies.

Burford Capital Announces Date for Release of 2023 Financial Results and Results Call Registration and Participation Details

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 7, 2024 /PRNewswire/ -- Burford Capital Limited ("Burford"), the leading global finance and asset management firm focused on law, today announces that it will release its financial results for the year ended December 31, 2023 ("FY23") and the three months ended December 31, 2023 ("4Q23") on Thursday, March 14, 2024, at 7.00am EDT / 11.00am GMT.

Key Points: 
  • NEW YORK, March 7, 2024 /PRNewswire/ -- Burford Capital Limited ("Burford"), the leading global finance and asset management firm focused on law, today announces that it will release its financial results for the year ended December 31, 2023 ("FY23") and the three months ended December 31, 2023 ("4Q23") on Thursday, March 14, 2024, at 7.00am EDT / 11.00am GMT.
  • Burford will hold a conference call for investors and analysts at 8.00am EDT / 12.00pm GMT on Thursday, March 14, 2024.
  • To minimize the risk of delayed access, participants are urged to dial into the conference call by 7.40am EDT / 11.40am GMT.
  • A live webcast of the call will also be available at https://events.q4inc.com/attendee/461322893 , and pre-registration at that link is encouraged.

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Tuesday, March 5, 2024

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • The Alamar products represent a significant advancement in Alzheimer's Disease research, says Dr. Henrik Zetterberg.
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Tuesday, March 5, 2024

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • We have also partnered with ALZpath, Inc. to bring the performance of their industry standard pTau217 antibody to a new level of sensitivity."
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.